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aim: Diabetes in pregnancy is a major burden with acute and long-term consequences. 
Its treatment requires adequate diagnosis and monitoring of therapy. Many experimental 
research on diabetes during pregnancy has been performed in rats. Recently, contin-
uous blood glucose monitoring of non-pregnant diabetic rats revealed an increased 
circadian variability of blood glucose that made a single blood glucose measurement per 
day inappropriate to reflect glycemic status. Continuous blood glucose measurement 
has never been performed in pregnant rats. We wanted to perform continuous blood 
glucose monitoring in pregnant rats to decipher the influence of pregnancy on blood 
glucose in diabetic and normoglycemic status.
Methods: We used the transgenic Tet29 diabetes rat model with an inducible knock 
down of the insulin receptor via RNA interference upon application of doxycycline (DOX) 
leading to insulin resistant type II diabetes. All Tet29 rats received a HD-XG telemetry 
implant (Data Sciences International, USA) that measured blood glucose and activity 
continuously. Rats were divided into four groups and blood glucose was monitored until 
end of pregnancy or the corresponding period: Tet29 + DOX (diabetic) non-pregnant, 
Tet29 + DOX (diabetic) pregnant, Tet29 (normoglycemic) non-pregnant, Tet29 (normo-
glycemic) pregnant.
results: All analyzed rats displayed a circadian variation in blood glucose concentra-
tion. Circadian variability was much more pronounced in pregnant diabetic rats than 
in normoglycemic pr egnant rats. Pregnancy ameliorated variation in blood glucose in 
diabetic situation. Pregnancy continuously decreased blood glucose during normoglyce-
mic pregnancy. Diabetic rats were less active than normoglycemic rats. We performed a 
calculation showing that application of continuous blood glucose measurement reduces 
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animal numbers needed to detect a given effect in experimental setting by decreasing 
variability and SD.
interpretation: Continuous blood glucose monitoring via a telemetry device in pregnant 
rats provides a more informative picture of the glycemic situation in comparison to single 
measurements. This could improve diagnosis and therapy of diabetes, decrease animal 
numbers within experimental settings, and add another physiological parameter (activity) 
to the analysis that could be helpful in testing therapeutic concepts targeting blood 
glucose levels and peripheral muscle function. We propose continuous glucose monitor-
ing as a new tool for the evaluation of pregnant diabetic rats.
Keywords: continuous glucose monitoring, pregnancy, diabetes, rat, circadian variation
inTrODUcTiOn
Preexisting diabetes during pregnancy and gestational diabetes 
are a major burden in modern western countries with increasing 
incidence. It causes not only acute obstetric and neonatal prob-
lems (1, 2) but also influences offspring health in later life (3, 4). 
Correct diagnosis and adequate therapies are required to face 
diabetes in pregnancy. Many experimental research on diabetes 
during pregnancy has been performed in rats (5, 6). Although 
human pregnancy is unique and no animal model provides com-
pletely comparable features to human reproduction, the rat offers 
important similarities to human pregnancy such as hemochorial 
placentation with deeply into the uterus invading trophoblast 
cells that mediate uterine spiral artery remodeling (7). This makes 
the rat an appropriate model to study human pregnancy.
It has long been known that there is a circadian rhythm of 
insulin secretion and blood glucose concentration in rats (8). Rats 
are nocturnal animals peaking with their activity, food intake, 
blood glucose, and insulin secretion at night (9). Recently, it has 
been shown by continuous blood glucose monitoring that the dif-
ference in mean night and mean day blood glucose concentration 
is less than 10 mg/dL in healthy male rats (10). Interestingly, the 
circadian variations in blood glucose concentrations are much 
more pronounced in male diabetic rats with a difference in mean 
night and mean day blood glucose concentration of more than 
140 mg/dL (10). The authors suggested that the perceived out-
come of an antidiabetic treatment may depend on the timepoint 
of glycemic control (10) and since blood glucose is assessed most 
often in the morning of a working day, primarily for practical 
reasons, when blood glucose concentration is low, the efficiency 
of experimental interventions is most likely overestimated in 
many animal studies (10).
A continuous blood glucose measurement has never been per-
formed in pregnant rats. We wanted to perform continuous blood 
glucose measurement in pregnant rats to decipher the influence of 
pregnancy on blood glucose in diabetic and normoglycemic status.
MaTerials anD MeThODs
Tet29 insulin receptor Knock Down  
rat Model
The animal work has been conducted according to national and 
international guidelines. The animal study was prospectively 
approved by the local authorities and the animal research ethics 
committee of Berlin, Germany (both Landesamt für Gesundheit 
und Soziales, approval number G 0157/13) and the animal wel-
fare body of the Max Delbrück Center for Molecular Medicine 
in the Helmholtz Association. We applied the transgenic Tet29 
diabetic rat model of insulin resistance (6, 11, 12) (RGD Cat# 
2313734, RRID:RGD_2313734), which had been developed on 
a Sprague-Dawley background by Dr. Michael Bader and his 
colleagues at the Max Delbrück Center for Molecular Medicine in 
the Helmholtz Association (11). Animals used in this study were 
obtained from this breed. The insulin receptor is knocked down 
via RNA interference (induction of small hairpin RNA) upon 
doxycycline (DOX) administration leading to insulin resistance 
and hyperglycemia. Without DOX, the Tet construct is silent 
due to the block of shRNA transcription by the Tet repressor. All 
rats were kept under standard conditions in cages in the animal 
house of the Max Delbrück Center for Molecular Medicine in 
the Helmholtz Association (average 22°C room temperature and 
12-/12-h light/dark cycle). The rats had ad libitum access to food and 
drinking water. Rats received an energy reduced diet (9.1 MJ/kg, 
from ssniff Spezialdiäten GmbH, Soest, Germany) according 
to the policy of the animal house at the time experiments were 
performed in 2014 and 2015. The rats were monitored regularly, 
at least once a day, with evaluation of their physical appearance 
(e.g., rat fur), behavior, activity, and eating and drinking amounts. 
Animals were weighed twice a week. At the end of the experiment, 
all rats and their pups were deeply anesthetized with isoflurane 
and sacrificed by decapitation.
implantation of the hD-Xg glucose 
Telemetry Transmitter
The HD-XG glucose telemetry transmitter from Data Sciences 
International (DSI, USA) monitors blood glucose, physical 
activity, and core body temperature (data not shown). Sixteen 
female Tet29 rats were used in the following study (Figure 1A). 
The blood glucose sensor was introduced infrarenally into 
the abdominal aorta and the transmitter was sutured to the 
peritoneum. The glucose sensor connector was fixed to the back 
musculature (left of the vena cava in the region of the iliolumbal 
veins). The reference electrode was fixed to the inner abdominal 
wall. The implantation of the glucose telemetry device was per-
formed under isoflurane anesthesia and all efforts were made to 
FigUre 1 | Experimental design and continuous blood glucose monitoring during pregnancy. (a) Shown is the experimental design of each rat participating in the 
study; DOX = Doxycyclin. (B) Shown is the mean blood glucose course of each rat per group over time; n = 3 non-pregnant Tet29 rats, n = 3 pregnant Tet29 rats, 
n = 5 non-pregnant Tet29 + DOX rats, and n = 5 pregnant Tet29 + DOX rats. The bold line/symbols show the smoothed averaged course of all animals within a 
group (LOESS). The days refer to pregnancy or the corresponding period in non-pregnant animals. Tet29 rats were normoglycemic, Tet29 + DOX rats were 
hyperglycemic. (a) Tet29 + DOX rats, both pregnant and non-pregnant, had higher blood glucose values than Tet29 rats, both pregnant and non-pregnant (repeated 
measures ANOVA). (b) In addition, pregnant Tet29 + DOX rats had higher blood glucose values than pregnant Tet29 rats (repeated measures ANOVA), and (c) 
non-pregnant Tet29 + DOX rats had higher blood glucose values than non-pregnant Tet29 rats (repeated measures ANOVA). (d) Blood glucose values decreased 
during pregnancy in Tet29 rats (ANOVA). (e) In these rats, blood glucose values during late pregnancy were lower than the blood glucose values of non-pregnant 
Tet29 rats in the corresponding period (post-hoc comparison). Pregnancy did not have an influence on mean blood glucose values in diabetic Tet29 + DOX rats 
(repeated measures ANOVA; post-hoc comparison), but there is (f) a significant change in blood glucose values over time in non-pregnant Tet29 + DOX rats (ANOVA).
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minimize suffering. The rats received carprofen 5 mg/kg body 
weight subcutaneously for analgesia before the surgery and 
on the day after. Two percent lidocaine gel was applied on the 
wound at the skin for further analgesia. The wounds were inves-
tigated daily to diagnose potential infections and dehiscences 
immediately.
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A two-point calibration of the HD-XG transmitter was per-
formed between 2 and 4 days after implantation of the HD-XG in 
all rats and in three rats additionally 5, 9, or 10 days after implanta-
tion. In one rat, initial calibration had to be repeated 5 and 7 days 
after implantation of the transmitter. Two-point calibration was 
conducted by measuring blood glucose concentration manually 
with the Accu-Chek Aviva device (Roche, Germany) by puncture 
of the tail vein before and after the intraperitoneal injection of 
glucose 2–2.7 g/kg body weight and adjusting measurement of the 
HD-XG device accordingly. After injection of glucose 2–2.7g/kg 
body weight, the blood glucose increased in average by 247 up 
to 349 mg/dL (mean based on one calibration result per rat, in 
the case of several calibrations, the result of the last calibration is 
used). The calibration was repeated in the case of inappropriate 
blood glucose increase. After successful initial calibration, the 
HD-XG device was calibrated at least twice a week with a single 
blood glucose concentration obtained manually by puncture of 
the tail vein and adjustment of the HD-XG device accordingly.
experimental Design
We investigated four experimental groups: pregnant and non-
pregnant Tet29 rats without DOX application (n  =  3 each), 
and pregnant and non-pregnant Tet29 +  DOX rats with DOX 
application (n = 5 each) making a total of 16 analyzed female rats 
(Figure 1A). In all rats, experiment started with telemetric device 
implantation and one or several blood glucose calibrations. All rats 
were analyzed until the end of the experiment on the morning of 
pregnancy day 22 (or the respective time point in non-pregnant 
rats). The presence of a vaginal plug was considered pregnancy 
day 1. Tet29 +  DOX rats received 2  mg/kg body weight DOX 
several days before conception and mating started when blood 
glucose ranged between 303 and 388 mg/dL. DOX administra-
tion was stopped on pregnancy day 1 and re-started on pregnancy 
day 15 or 16 until pregnancy day 21 or 22. Pregnant Tet29 rats had 
12 pups each, pregnant Tet29 + DOX rats had between 9 and 13 
pups. Non-pregnant Tet29 rats were not mated. Non-pregnant 
Tet29 + DOX rats had been mated and a vaginal plug was vis-
ible on pregnancy day 1, but at the time of sacrifice/end of the 
experiment, their uterus resembled the one of non-pregnant rats 
(no fetuses, no resorptions, no implantation sites, no other signs 
of pregnancy). Blood pressure measurement under anesthesia 
received two pregnant Tet29 + DOX rats on pregnancy day 19, 
four non-pregnant Tet29 + DOX rats between the respective time 
point of pregnancy day 17 and 19, and all three pregnant Tet29 
rats on pregnancy day 18 or 19 (data not shown).
continuous Blood glucose Measurement 
and statistical analysis
The HD-XG device enabled continuous blood glucose measure-
ment. Blood glucose concentrations in the descending aorta were 
recorded and analyzed every minute for 23 days (24-h period) 
in rats maintained in a 12-/12-h light/dark cycle (light on from 
6:00  am until 5:59  pm and light off from 6:00  p.m. until 5:59 
a.m.). Each rat generated over 29,700 individual blood glucose 
measurements (median about 32,400) and 529 activity counts 
(median 552). Activity counts were summed up over 1-h periods.
We focused our statistical analysis on the time period from 
pregnancy day −1 until pregnancy day 21 (or the respective time 
period in non-pregnant animals). Pregnancy itself was defined 
as pregnancy day 1 until pregnancy day 21 (including pregnancy 
day 21). Time periods were defined by day as early pregnancy 
(day 1 until day 9), mid pregnancy (day 10 until day 15), and late 
pregnancy (day 16 until day 21).
The animal experiment was stopped at the morning of preg-
nancy day 22 at 5:59  a.m. In our statistical analysis, days were 
defined as the light period between 6:00  a.m. until 5:59  p.m. 
and nights were defined as the dark period from 6:00 p.m. until 
5:59 a.m. Therefore, the statistical analysis included 21 days (24-h 
periods) of pregnancy. Statistical analysis of non-pregnant Tet29 
rats started 8 days after implantation of the device, rather similar 
to the time point of the pregnant Tet29 rats.
Statistical analysis started with an exploratory analysis and 
the generations of raw data plots (Figure S1 in Supplementary 
Material). Data were then subjected to a time series analysis 
and variability was split into the components diurnal rhythm, 
long-term trend, and remaining random variability (noise; not 
shown). Outlier detection was based on noise since day/night 
rhythm would potentially mask extreme values. Extreme values 
were replaced by the mean of the previous 10 measurements 
before further analysis. Repeated measures ANOVA, based 
on daily (24-h period) mean values during pregnancy or the 
corresponding period in non-pregnant animals, was applied 
to test the influence of pregnancy on diabetic Tet29 +  DOX 
rats (Figures  1B, 2 and 3) and on normoglycemic Tet29 rats 
(Figures 2 and 3), and to test the influence of DOX (diabetes) 
on pregnant rats (Figures 1B, 2B and 3), on non-pregnant rats 
(Figures  1B, 2B and 3), as well as on all rats (Figures  1B, 2B 
and 3). t-test as post-hoc exploratory analysis, based on period 
average values (p-values with adjustment for multiple testing by 
false discovery rate), was applied to further analyze the influ-
ence of pregnancy (early, mid, and late pregnancy) on diabetic 
Tet29 + DOX rats (Figures 1B and 2C) and on normoglycemic 
Tet29 rats (Figures 1B and 2D). ANOVA, based on period aver-
age values, was performed to test the influence of time in diabetic 
Tet29 + DOX rats (Figure 1B) and in normoglycemic Tet29 rats 
(Figure 1B). P ≤ 0.05 were considered significant and marked 
with *. p ≤ 0.01 were marked with ** and p ≤ 0.001 were marked 
with ***. Statistical analysis was conducted using R (R Core Team 
(2017). R: A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, Austria. 
https://www.R-project.org/).
resUlTs
continuous Blood glucose Monitoring 
During rat Pregnancy
Tet29 + DOX rats, both pregnant and non-pregnant, had signifi-
cantly higher blood glucose values than Tet29 rats, both pregnant 
and non-pregnant (mean blood glucose during pregnancy or 
the corresponding period in non-pregnant rats of 352 ±  114 
vs. 112 ± 12 mg/dL, p = 0.001; Figure 1Ba). The blood glucose 
values initially increased in most Tet29 + DOX rats, followed by 
FigUre 2 | Circadian variation of blood glucose during pregnancy. (a) Diurnal variability of blood glucose per group between pregnancy day 5 and 7 or the 
corresponding period in non-pregnant rats. Data were first averaged over animals within groups for every minute, then smoothed by moving average. 
DOX = Doxycyclin; There is a circadian variation of blood glucose in all four groups with higher values at night. (B) Shown is the mean difference ± SD between  
mean night and mean day blood glucose during pregnancy or the corresponding period per group. Tet29 + DOX rats, both pregnant and non-pregnant, had a higher 
difference in night and day blood glucose values than Tet29 rats, both pregnant and non-pregnant (repeated measures ANOVA). In addition, pregnant Tet29 + DOX 
rats had a higher difference in night and day blood glucose values than pregnant Tet29 rats (repeated measures ANOVA), and non-pregnant Tet29 + DOX rats had a 
higher difference in night and day blood glucose values than non-pregnant Tet29 rats (repeated measures ANOVA). (c) Shown is the mean difference ± SD between 
mean night and mean day blood glucose during the different periods of pregnancy or the corresponding periods in non-pregnant rats within the Tet29 + DOX rats. 
Pregnancy decreased the difference between night and day blood glucose in diabetic Tet29 + DOX rats during late pregnancy (post-hoc comparison). (D) Shown is 
the mean difference ± SD between mean night and mean day blood glucose during the different periods of pregnancy or the corresponding periods in non-pregnant 
rats within the Tet29 rats. Pregnancy had no effect on the difference between night and day blood glucose in normoglycemic Tet29 rats during any time period of 
pregnancy (post-hoc comparison). (a–D) n = 3 non-pregnant Tet29, n = 3 pregnant Tet29, n = 5 non-pregnant Tet29 + DOX, n = 5 pregnant Tet29 + DOX.
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a decrease and a second increase. Tet29 rats were normoglycemic 
with maximum blood glucose values of 133 mg/dL during preg-
nancy or the corresponding period in non-pregnant Tet29 rats.
When considering pregnant rats only, Tet29  +  DOX rats 
had as well significantly higher blood glucose values than Tet29 
rats (mean blood glucose during pregnancy of 377 ±  107 vs. 
FigUre 3 | Continuous monitoring of activity during pregnancy. Shown is the mean activity of each rat per group over time. DOX = Doxycyclin; n = 3 non-pregnant 
Tet29 rats, n = 3 pregnant Tet29 rats, n = 5 non-pregnant Tet29 + DOX rats, and n = 5 pregnant Tet29 + DOX rats. The bold line/symbols show the smoothed 
averaged course of all animals within a group (LOESS). The days refer to pregnancy or the corresponding period in non-pregnant animals. (a) Diabetic Tet29 + DOX 
rats, both pregnant and non-pregnant, display a lower activity than normoglycemic Tet29 rats, both pregnant and non-pregnant (repeated measures ANOVA). (b) In 
addition, non-pregnant Tet29 + DOX rats had a lower activity than non-pregnant Tet29 rats (repeated measures ANOVA). There is no difference in activity between 
pregnant Tet29 + DOX rats and pregnant Tet29 rats (repeated measures ANOVA). Pregnancy did not influence activity in diabetic Tet29 + DOX rats (repeated 
measures ANOVA), but there was a trend that pregnancy decreased activity in normoglycemic Tet29 rats (repeated measures ANOVA).
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105 ± 9 mg/dL, p = 0.001; Figure 1Bb). In addition, also in non-
pregnant status, Tet29 + DOX rats had significantly higher blood 
glucose values than Tet29 rats (mean blood glucose during the 
corresponding period of pregnancy of 328 ± 99 vs. 118 ± 7 mg/dL, 
p = 0.001; Figure 1Bc).
Pregnancy Decreases Blood glucose 
Values in normoglycemic rats
Blood glucose values decreased continuously during pregnancy 
in normoglycemic Tet29 rats and were significantly different over 
time (mean blood glucose of 112 ± 2 mg/dL in early, 104 ± 6 mg/dL 
in mid, and 96  ±  3  mg/dL in late pregnancy; p  =  0.030; 
Figure 1Bd). The mean blood glucose decreased about 16 mg/dL 
from early to late pregnancy in Tet29 rats. This led to significantly 
lower blood glucose values during late pregnancy in comparison 
to the blood glucose values of non-pregnant Tet29 rats in the 
corresponding period (96 ±  3 vs. 117 ±  6  mg/dL; p =  0.004; 
Figure  1Be). Non-pregnant Tet29 rats did not display such a 
prominent change in blood glucose values over time (mean blood 
glucose of 121 ± 6 mg/dL, 114 ± 3 mg/dL, and 117 ± 6 mg/dL 
in the corresponding period to early, mid, and late pregnancy, 
respectively, p = 0.372; Figure 1B). The blood glucose values of 
Tet29 rats during early and mid pregnancy were not significantly 
different in comparison to the blood glucose values of non-
pregnant Tet29 rats in the corresponding period (p = 0.102 and 
p = 0.072, respectively; Figure 1B).
Pregnancy Decreases Variation in Blood 
glucose Values in Diabetic rats
Pregnancy did not have a significant influence on mean blood 
glucose values in diabetic rats (p = 0.315; Figure 1B). The blood 
glucose values of Tet29 + DOX rats during early, mid, and late 
pregnancy were not significantly different to blood glucose values 
of non-pregnant Tet29 + DOX rats in the corresponding period 
(mean blood glucose of 407 ± 71 mg/dL in early, 350 ± 123 mg/dL in 
mid, and 357 ± 133 mg/dL in late pregnancy vs. 399 ± 12 mg/dL 
(p = 0.808), 245 ± 72 mg/dL (p = 0.140), and 306 ± 42 mg/dL 
(p = 0.451) in the corresponding period to early, mid, and late 
pregnancy). But when focusing on the blood glucose course 
within each group, the non-pregnant Tet29 +  DOX rats had a 
significant change in blood glucose values over time (p = 0.001; 
Figure 1Bf). There was a decrease in blood glucose of 154 mg/dL 
from the early to the mid period followed by an increase of 
blood glucose of 61  mg/dL from the mid to the late period in 
non-pregnant Tet29 +  DOX rats. Pregnant Tet29 +  DOX rats 
did not display such a prominent change in blood glucose values 
over time (p = 0.121; Figure 1B). Blood glucose decreased about 
57 mg/dL from early to mid pregnancy and increased about 7 mg/dL 
from mid to late pregnancy in pregnant Tet29 rats.
Diabetes increases circadian Variation  
in Blood glucose in Pregnant rats
There was a circadian variation of blood glucose in all rats, 
independent of pregnancy and diabetic status (Figure  2A). 
Blood glucose was highest around 8 p.m. (2 h after start of dark 
cycle) and lowest around 2 p.m. (8 h after initiation of light cycle) 
within 24  h (Figure  2A). There was a continuous decrease in 
blood glucose over 18 h from 8 to 2 p.m., followed by a faster 
(over 6 h), but still continuous increase in blood glucose from 
2 until 8  p.m. (Figure  2A). Diabetic Tet29 +  DOX rats, both 
pregnant and non-pregnant, had a significantly higher difference 
in night and day blood glucose values than normoglycemic Tet29 
rats, both pregnant and non-pregnant (mean difference between 
mean night and mean day blood glucose during pregnancy or 
FigUre 4 | Simulation on sample size requirements. Simulation to evaluate 
the effect of continuous blood glucose measurement on sample size 
requirements. The simulation is based on 1,000 simulation runs with 100 
animals per run. SD of continuous blood glucose measurements and single 
measurements is computed and aggregated over simulations. The sample 
size necessary to detect a 10% mean change with 80% power is computed 
based on average SD. The single measurement-based analysis 
overestimates the within-sample variability. With a “true” SD of 6, the single 
measurement-based analysis estimates an SD of 12.5, whereas the 
continuous blood glucose measurement-based analysis estimates an SD of 
6.0. This results in larger sample sizes required to detect a given effect in 
single measurement-based analysis (19 vs. 6 in continuous blood glucose 
measurement-based analysis).
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the corresponding period in non-pregnant rats of 35 ±  30 vs. 
2.7 ± 4.0 mg/dL, p = 0.001; Figure 2B).
When considering pregnant rats only, diabetic Tet29 + DOX 
rats had as well a significantly higher difference in night and day 
blood glucose values than normoglycemic Tet29 rats (mean dif-
ference between mean night and mean day blood glucose during 
pregnancy of 26 ± 29 vs. 3.0 ± 3.4 mg/dL, p = 0.006; Figure 2B). 
In addition, also in non-pregnant status, diabetic Tet29 + DOX 
rats had a significantly higher difference in night and day blood 
glucose values than normoglycemic Tet29 rats (mean difference 
between mean night and mean day blood glucose during the cor-
responding period of pregnancy of 45 ± 27 vs. 2.4 ± 4.6 mg/dL, 
p = 0.001; Figure 2B).
Pregnancy Decreases circadian Variation 
in Blood glucose in Diabetic rats
Pregnancy significantly decreased the mean difference between 
mean night and mean day blood glucose in diabetic Tet29 + DOX 
rats (p = 0.007; repeated measures ANOVA). The mean difference 
between mean night and mean day blood glucose during late 
pregnancy was significantly smaller than the one of non-pregnant 
Tet29 + DOX rats during the corresponding period (29 ± 37 vs. 
70 ± 15 mg/dL; p = 0.049; Figure 2C). There was no significant 
change in mean difference between mean night and mean day 
blood glucose between pregnant and non-pregnant Tet29 + DOX 
rats during early and mid pregnancy or the corresponding period 
(early pregnancy 31.5 ± 13.5 vs. corresponding period 35 ± 9 mg/dL, 
p = 0.655; mid pregnancy 15.0 ± 16.3 vs. corresponding period 
32 ± 10 mg/dL, p = 0.079; Figure 2C).
Pregnancy did not significantly influence mean difference 
between mean night and mean day blood glucose in normoglyce-
mic Tet29 rats (p = 0.732; repeated measures ANOVA). The mean 
difference between mean night and mean day blood glucose val-
ues was 2.3 ± 1.5 mg/dL in early, 1.89 ± 0.67 mg/dL in mid, and 
5.3 ± 1.1 mg/dL in late pregnancy in normoglycemic Tet29 rats 
in comparison to 1.9 ± 3.7 mg/dL (p = 0.852), 1.5 ± 4.4 mg/dL 
(p = 0.900), and 4.0 ± 2.2 mg/dL (p = 0.434) in non-pregnant 
Tet29 rats in the corresponding periods (Figure 2D).
Diabetes reduces activity in rats
Besides continuous blood glucose monitoring, the telemetric 
device enabled also monitoring of activity (Figure 3). Diabetic 
Tet29 + DOX rats, both pregnant and non-pregnant, had a sig-
nificantly lower activity than normoglycemic Tet29 rats, both 
pregnant and non-pregnant (mean activity during pregnancy 
or the corresponding period in non-pregnant rats of 69 ± 57 vs. 
115 ± 95 arbitrary units, p = 0.001; Figure 3a).
When considering pregnant rats only, there was no significant 
difference in activity between diabetic Tet29 +  DOX rats and 
normoglycemic Tet29 rats (mean activity during pregnancy 
of 72 ± 17 vs. 92 ± 34 arbitrary units, p = 0.215, Figure 3). In 
non-pregnant status, Tet29 + DOX rats had significantly lower 
activity than normoglycemic Tet29 rats (mean activity during the 
corresponding period of pregnancy of 67 ± 25 vs. 139 ± 32 arbi-
trary units, p = 0.001; Figure 3b). Pregnancy neither significantly 
influenced the activity in diabetic Tet29 + DOX rats (p = 0.680; 
Figure 3) nor in normoglycemic Tet29 rats (p = 0.084; Figure 3), 
but there was a trend to lower activity in pregnant Tet29 rats in 
comparison to non-pregnant Tet29 rats.
continuous Blood glucose Monitoring 
reduces sample size
Finally, we evaluated the effect of continuous blood glucose 
measurement on sample size requirements (Figure  4). Based 
on the experience of our analysis, we simulated a scenario to 
calculate the sample size necessary to detect a 10% mean change 
with 80% power based on average SD. Continuous blood glucose 
measurement provides a lower variability and thus lower SD in 
measured values than single measurement (SD of 6.0 vs. SD of 
12.5 within single measurement), which results in smaller sample 
sizes required to detect a given effect (n = 6 vs. n = 19 within a 
single measurement analysis).
DiscUssiOn
We successfully employed the method of continuous blood 
glucose and activity measurement during rat pregnancy in 
normoglycemic and diabetic status. We showed that (1) preg-
nant diabetic rats display a much more pronounced circadian 
variation in blood glucose than normoglycemic pregnant rats, 
(2) pregnancy ameliorates variation in blood glucose in diabetic 
status, and (3) pregnancy continuously decreases blood glucose 
during normoglycemic pregnancy. In addition, we showed that 
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(4) diabetes reduces activity in non-pregnant rats, and we (5) 
simulated that application of continuous blood glucose measure-
ment could reduce sample size. To the best of our knowledge, this 
has not been described before.
It has already been shown by other authors that diabetes 
increases circadian variability of blood glucose in non-pregnant 
rats (10). We provide data that this phenomenon applies for 
pregnant rats as well. The difference between night and day blood 
glucose was not just absolutely higher in diabetic pregnant rats in 
comparison to normoglycemic pregnant rats, it is also relatively 
higher with regard to the mean blood glucose during pregnancy 
(6.9 vs. 2.9%). Interestingly, pregnancy reduced the circadian 
variation in blood glucose and the variation in blood glucose 
within time in the diabetic rats of our study. We are not aware 
of literature about this phenomenon, but propose future stud-
ies to further elucidate blood glucose variation during diabetic 
pregnancy. After all, it is not fully understood to which extent 
high blood glucose during diabetic pregnancy and the variation 
in blood glucose within diabetic pregnancy harms the fetus. We 
interpret our data of reduced glucose variation during diabetic 
pregnancy as a protective mechanism to supply the fetus with 
continuous blood glucose. One could speculate that this protec-
tive mechanism might be reduced or missing in diabetic pregnan-
cies with very severe fetal outcome.
Although pregnancy reduced circadian variation in blood glu-
cose and the variation in blood glucose with time in the diabetic 
rats of our study, we did not see an influence of pregnancy on 
mean blood glucose values. Owing to our rat model, we had to 
apply DOX to induce diabetes. DOX application was stopped on 
pregnancy day 1 (or the corresponding period in non-pregnant 
animals) to reduce embryo-/fetotoxicity and to avoid a further 
increase in blood glucose. DOX was re-started on pregnancy day 
15 or 16 (or the corresponding period in non-pregnant animals). 
The blood glucose values of most of the analyzed diabetic rats 
mirror this DOX protocol with an initial increase of blood 
glucose, followed by a decrease and a second increase of blood 
glucose values. Thus, we cannot conclude that the blood glucose 
course we analyzed is the typical one of diabetic pregnant rats. It 
might well be that DOX application had masked an increase or 
decrease of blood glucose during “natural” diabetic rat pregnancy. 
But we were able to analyze the influence of pregnancy in our rat 
diabetes model by comparison with non-pregnant diabetic rats, 
which were also treated with DOX, to reveal the difference in 
variation in blood glucose values mentioned above.
Although human pregnancy induces peripheral insulin resist-
ance (13), most women display normal glucose tolerance during 
pregnancy due to increased insulin secretion (13). We are not 
aware of any studies on physiological blood glucose courses dur-
ing normoglycemic pregnancy in humans or rodents. Our study 
revealed a decrease in blood glucose throughout normoglycemic 
rat pregnancy. The low blood glucose in the rat at late pregnancy 
might be the result of the increasing nutritional demand of the 
fetus possibly triggered by increased maternal insulin secretion. 
We cannot make any statements about insulin secretion in the 
normoglycemic pregnant rats of our study and thus propose 
future studies on physiological insulin secretion and insulin 
resistance during rat pregnancy.
Interestingly, our study also revealed that diabetes enormously 
reduces activity in non-pregnant rats. Diabetes is often consid-
ered a consequence of sedentary lifestyle. Our data propose that 
it could work reversely as well. The association between insulin 
resistance/diabetes and reduced activity is not fully understood 
so far. Insulin resistance might lead to decreased glucose uptake 
of skeletal muscle decreasing its function. During heart failure, 
which is often accompanied by insulin resistance, metabolic failure 
of the myocardium and of peripheral tissues has been described in 
Ref. (14). Rat activity can be used as a parameter for skeletal 
muscle function and energy consumption which are of rele-
vance when analyzing blood glucose and insulin metabolism. 
In addition, the HD-XG device could be a valuable tool to test 
therapeutic concepts targeting blood glucose levels and peri phe-
ral muscle function (activity). Our data show that pregnancy does 
not influence activity in diabetic status, which might be because 
diabetic rats generally move less and a further decrease due to 
pregnancy would not be relevant. Pregnancy also did not influ-
ence activity in normoglycemic rats of our study, but there was 
a clear trend toward less activity during pregnancy which might 
not have become significant due to the low animal numbers used 
(n = 3 vs. n = 3).
The circadian variation leads to a significant change in blood 
glucose making a random single blood glucose value within an 
experiment an inappropriate parameter to analyze the glycemic 
status of a rat, especially when performed at different time points 
during the day. This problem aggravates when evaluating diabetic 
rats. Random fluctuation further increases within-animal varia-
tion in blood glucose in diabetic rats. We thus propose continu-
ous blood glucose measurement via telemetric device in pregnant 
and non-pregnant diabetic rats to improve data quality. In theory, 
repetitive single blood glucose measurements could also provide 
continuous blood glucose monitoring, but they are impractical to 
conduct and accompanied by stress for the animal, which would 
confound the results. Importantly, besides improvement of data 
quality, continuous blood glucose monitoring could reduce the 
number of required samples to detect a given effect. There would 
be a reduction of more than 68% of animals needed in our calcu-
lated scenario. This supports the three Rs (Replace, Reduce, and 
Refine), the guiding principles underlying animal use in scientific 
research.
limitations of the study
Limitations of our study are the low animal numbers we used 
and the partly different treatment between the animal groups 
(e.g., different timepoint and number of calibrations, different 
total DOX dosages, and blood pressure measurement under 
short-time anesthesia in some animals). Another limitation is 
that Data Sciences International (DSI, USA) guarantees 30 days 
of continuous blood glucose measurement with their HD-XG 
glucose telemetry transmitter, but we used the transmitter 
between 31 and 41  days due to the long study protocol with 
pregnancy itself already lasting 22  days. Rats should recover 
at least 5  days after implantation of the glucose monitoring 
device before any manipulation like mating can start which 
then sometimes takes some days until successful conception 
happens. This makes it difficult to perform our analysis in 
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normoglycemic rats within 30 days, and it is even impossible to 
perform it in the diabetic rats, which need to become diabetic 
via DOX application for several days before mating. Although 
our raw data do not exhibit signs of device failure and the end 
of the warranty does not mean that the device stops functioning 
correctly, we cannot exclude any kind of device failure at the end 
of our study or differences between the groups in dependence 
of the duration of the device. Additional limitations are that 
we did not mate the non-pregnant animals with sterile males 
and that the diabetic animals we considered non-pregnant may 
have been briefly pregnant. These rats had a vaginal plug, a sign 
for copulation that is often used as a marker of pregnancy in 
healthy rats. In the diabetic rats of our model, however, fertility 
is decreased (data not shown), and pregnancy rates after vagi nal 
plug are lower than in healthy rats. It is very likely that the dia-
betic Tet29 rats we consider non-pregnant were never pregnant; 
however, we cannot exclude that they were pregnant for a couple 
of days before experiencing a very early pregnancy loss. Because 
of the limitations mentioned, our results need to be replicated 
in studies with larger sample size and different animal models.
cOnclUsiOn
Taken together, continuous blood glucose monitoring via telem-
etry device in pregnant and non-pregnant rats provides a more 
informative picture of the glycemic situation of an individual 
that could improve diagnosis and therapy of diabetes mellitus, 
decrease experimental animal numbers and add another physi-
ological parameter (activity) to the analysis.
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